Events - 30 Mar 13:00FDA public meeting on vitiligo

Event

Silver Spring, MD, USA

Due to extenuating circumstances, this meeting is postponed until further notice.

US Federal Drug Administration (FDA) is conducting its first public meeting on Patient-Focused Drug Development for Vitiligo.

The meeting is intended to allow FDA to obtain patient perspectives on the impact of vitiligo, including on daily life, patient views on treatment approaches, and decision factors taken into account when selecting a treatment.

You can participate in three ways: 

  1. Register, attend the meeting and take active part in discussions.
  2. Join webcast and comment throughout the live stream.
  3. Submit your online comments before the meeting.

WHEN: Monday, March 30, 2020 at 1 p.m. to 5 p.m.

WHERE: FDA White Oak Campus 10903 New Hampshire Ave. Building 31, Great Room Silver Spring, MD 20903

Discussion questions